Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers of Medicine"
DOI: 10.1007/s11684-021-0869-y
Abstract: Cabozantinib, mainly targeting cMet and vascular endothelial growth factor receptor 2, is the second-line treatment for patients with advanced hepatocellular carcinoma (HCC). However, the lower response rate and resistance limit its enduring clinical benefit. In… read more here.
Keywords: hepatocellular carcinoma; cmet inhibitor; rapamycin; cmet ... See more keywords